ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Effects of bevacizumab combined with anti-epidermal growth factor receptor monoclonal antibody-targeted drugs in patients with metastatic colorectal cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a common malignant tumor of the digestive system. The standard chemotherapy (CT) regimen for metastatic CRC (mCRC) is FOLFIRI, etc., but CT plus bevacizumab anti-epidermal growth factor receptor (EGFR)monoclonal antibody (mAb) (cetuximab) can improve the therapeutic effect. This article compared the effect of FOLFIRI plus bevacizumab on the clinical treatment of mCRC. One hundred eight patients with mCRC were divided into cohort A (CA, bevacizumab FOLFIRI CT, n = 50) and cohort B (CB, cetuximab + FOLFIRI CT, n = 58). All patients received 6 cycles of CT. The levels of tumor markers, angiogenic factors, and T lymphocyte subsets were compared, and the objective response rate (ORR) and disease control rate (DCR) were counted. The overall survival (OS), progression-free survival (PFS), and adverse reactions (AR) were recorded. There was no difference in DCR (82.0% vs 89.7%), serum tumor markers, angiogenic factors, T lymphocyte subsets (CD3 + , CD4 + , and CD8 +), and DFS (16.0% vs 24.1%) in subjects; as against CA, the ORR (62.0% vs 75.9%), CD4 + /CD8 + ratio, and OS (32.0% vs 46.6%) were significantly increased, and the VEGF level was significantly higher in CB (P < 0.05). Compared with bevacizumab plus FOLFIRI, cetuximab plus FOLFIRI has significantly higher ORR and longer OS in the treatment of patients with mCRC.
Indexed as
Identifiers
41483191What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.